MedTrace Logo

Melatonin's Effects on Treatment Of Diabetes Mellitus

NCT02691897 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-04-08

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy and safety of melatonin in control of blood sugar in patients with type 2 diabetes mellitus (DM).

Conditions

Interventions

DRUG

Melatonin

Melatonin 3mg once daily at bedtime

DRUG

Placebo

Placebo 1 tablet once daily at bedtime

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Kamran Bagheri Lankarani, M.D. · Health Policy Research Center, Shiraz University of Medical Sciences

  • Mesbah Shams, M.D. · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

  • Payam Peymani · Health Policy Research Center, Shiraz University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2020-05-31
Completion
2020-07-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691897 on ClinicalTrials.gov